GEN-MKT-18-7897-A
Feb 17, 2016 | Blogs, Environmental / Industrial, Food / Beverage | 0 comments
Between 3-6 November 2015, the Recent Advances in Food Analysis (RAFA) 2015 Symposium took place in Prague, Czech Republic.
With over 800 scientists in attendance, visitors were treated to 132 lectures, 15 seminars, 6 workshops and over 500 posters presenting the latest in food testing methodology. Amongst the hive of activity was our very own Andre Schreiber, presenting on ways to ignite your routine testing methods with new and existing technology.
If you were unable to attend RAFA 2015 or would like to see Andre’s talk again you can watch the full 45-minute seminar below.
Be sure to leave a comment below as Andre will be able to respond to any questions or feedback, and if you’d like to read more about the talk you can download the full Igniting Your Routine Testing Methods Presentation.Download the Full Presentation >
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network